Roche announced positive 96-week data for fenebrutinib in relapsing multiple sclerosis (RMS). The open-label extension study showed a very low annualized relapse rate and no disability progression in patients. MRI scans revealed suppressed brain disease activity with no new active lesions. The safety profile remained consistent with previous data, showing mostly mild adverse events. Three Phase III trials are underway, with results expected by the end of 2025. Fenebrutinib is a novel, reversible Bruton's tyrosine kinase (BTK) inhibitor. It targets both B-cell and microglia activation, potentially addressing disability progression. The Phase III program includes trials for both RMS and primary progressive multiple sclerosis (PPMS). Over 2700 patients have participated in fenebrutinib clinical trials across various diseases. Roche aims to develop innovative treatments for neurological disorders.